> 0 1 0 1 O
50 2 4 2 4 B-lower_bound
mL 5 7 5 7 I-lower_bound
/ 7 8 7 8 I-lower_bound
min 8 11 8 11 I-lower_bound
for 12 15 12 15 O
SRd 16 19 16 19 B-clinical_variable
Arm 20 23 20 23 I-clinical_variable

A 0 1 24 25 O
serious 2 9 26 33 O
psychiatric 10 21 34 45 B-chronic_disease
or 22 24 46 48 I-chronic_disease
medical 25 32 49 56 I-chronic_disease
condition 33 42 57 66 I-chronic_disease
which 43 48 67 72 O
, 48 49 72 73 O
in 50 52 74 76 O
the 53 56 77 80 O
opinion 57 64 81 88 O
of 65 67 89 91 O
the 68 71 92 95 O
Investigator 72 84 96 108 O
, 84 85 108 109 O
could 86 91 110 115 O
interfere 92 101 116 125 O
with 102 106 126 130 O
treatment 107 116 131 140 B-treatment

ANC 0 3 141 144 B-clinical_variable
≥ 4 5 145 146 O
1000 6 10 147 151 B-lower_bound
/ 10 11 151 152 I-lower_bound
mm3 11 14 152 155 I-lower_bound

Active 0 6 156 162 O
graft 7 12 163 168 B-chronic_disease
versus 13 19 169 175 I-chronic_disease
host 20 24 176 180 I-chronic_disease
disease 25 32 181 188 I-chronic_disease
after 33 38 189 194 O
allogeneic 39 49 195 205 B-treatment
stem 50 54 206 210 I-treatment
cell 55 59 211 215 I-treatment
transplantation 60 75 216 231 I-treatment

Active 0 6 232 238 O
plasma 7 13 239 245 B-cancer
cell 14 18 246 250 I-cancer
leukemia 19 27 251 259 I-cancer

Active 0 6 260 266 O
, 6 7 266 267 O
unstable 8 16 268 276 O
cardiovascular 17 31 277 291 B-chronic_disease
function 32 40 292 300 O

Adequate 0 8 301 309 O
hematopoietic 9 22 310 323 O
function 23 31 324 332 O
within 32 38 333 339 O
21 39 41 340 342 B-upper_bound
days 42 46 343 347 I-upper_bound
prior 47 52 348 353 I-upper_bound
to 53 55 354 356 O
C1 56 58 357 359 O
D1 59 61 360 362 O

Adequate 0 8 363 371 O
hepatic 9 16 372 379 O
function 17 25 380 388 O
within 26 32 389 395 O
21 33 35 396 398 B-upper_bound
days 36 40 399 403 I-upper_bound
prior 41 46 404 409 I-upper_bound
to 47 49 410 412 O
C1 50 52 413 415 O
D1 53 55 416 418 O

Adequate 0 8 419 427 O
renal 9 14 428 433 O
function 15 23 434 442 O
within 24 30 443 449 O
21 31 33 450 452 B-upper_bound
days 34 38 453 457 I-upper_bound
prior 39 44 458 463 I-upper_bound
to 45 47 464 466 O
C1 48 50 467 469 O
D1 51 53 470 472 O

Age 0 3 473 476 B-age
≥ 4 5 477 478 O
18 6 8 479 481 B-lower_bound
years 9 14 482 487 I-lower_bound
at 15 17 488 490 O
the 18 21 491 494 O
time 22 26 495 499 O
of 27 29 500 502 O
informed 30 38 503 511 O
consent 39 46 512 519 O

Any 0 3 520 523 O
active 4 10 524 530 O
gastrointestinal 11 27 531 547 B-chronic_disease
dysfunction 28 39 548 559 I-chronic_disease
that 40 44 560 564 O
prevents 45 53 565 573 O
the 54 57 574 577 O
patient 58 65 578 585 O
from 66 70 586 590 O
swallowing 71 81 591 601 O
tablets 82 89 602 609 O
or 90 92 610 612 O
interferes 93 103 613 623 O
with 104 108 624 628 O
absorption 109 119 629 639 O
of 120 122 640 642 O
study 123 128 643 648 B-treatment
treatment 129 138 649 658 I-treatment

Any 0 3 659 662 O
non 4 7 663 666 B-clinical_variable
- 7 8 666 667 I-clinical_variable
hematological 8 21 667 680 I-clinical_variable
toxicities 22 32 681 691 I-clinical_variable
( 33 34 692 693 O
except 34 40 693 699 O
for 41 44 700 703 O
peripheral 45 55 704 714 B-chronic_disease
neuropathy 56 66 715 725 I-chronic_disease
as 67 69 726 728 O
described 70 79 729 738 O
in 80 82 739 741 O
exclusion 83 92 742 751 O
criterion 93 102 752 761 O
# 103 104 762 763 O
24 104 106 763 765 O
) 106 107 765 766 O
that 108 112 767 771 O
patients 113 121 772 780 O
experienced 122 133 781 792 O
from 134 138 793 797 O
treatments 139 149 798 808 B-treatment
in 150 152 809 811 O
previous 153 161 812 820 B-treatment
clinical 162 170 821 829 I-treatment
studies 171 178 830 837 I-treatment
must 179 183 838 842 O
have 184 188 843 847 O
resolved 189 197 848 856 O
to 198 200 857 859 O
≤ 201 202 860 861 O
Grade 203 208 862 867 B-upper_bound
2 209 210 868 869 I-upper_bound
by 211 213 870 872 O
Cycle 214 219 873 878 O
1 220 221 879 880 O
Day 222 225 881 884 O
1 226 227 885 886 O

Blood 0 5 887 892 B-treatment
( 6 7 893 894 I-treatment
or 7 9 894 896 I-treatment
blood 10 15 897 902 I-treatment
product 16 23 903 910 I-treatment
) 23 24 910 911 I-treatment
transfusions 25 37 912 924 I-treatment
and 38 41 925 928 O
blood 42 47 929 934 B-treatment
growth 48 54 935 941 I-treatment
factors 55 62 942 949 I-treatment
within 63 69 950 956 O
7 70 71 957 958 B-upper_bound
days 72 76 959 963 I-upper_bound
of 77 79 964 966 O
C1D1 80 84 967 971 O
( 85 86 972 973 O
only 86 90 973 977 O
for 91 94 978 981 O
patients 95 103 982 990 O
enrolling 104 113 991 1000 O
into 114 118 1001 1005 O
the 119 122 1006 1009 O
Expansion 123 132 1010 1019 O
Phase 133 138 1020 1025 O
) 138 139 1025 1026 O

Congestive 0 10 1027 1037 B-chronic_disease
heart 11 16 1038 1043 I-chronic_disease
failure 17 24 1044 1051 I-chronic_disease
( 25 26 1052 1053 I-chronic_disease
CHF 26 29 1053 1056 I-chronic_disease
) 29 30 1056 1057 I-chronic_disease
of 31 33 1058 1060 O
New 34 37 1061 1064 B-clinical_variable
York 38 42 1065 1069 I-clinical_variable
Heart 43 48 1070 1075 I-clinical_variable
Association 49 60 1076 1087 I-clinical_variable
( 61 62 1088 1089 I-clinical_variable
NYHA 62 66 1089 1093 I-clinical_variable
) 66 67 1093 1094 I-clinical_variable
Class 68 73 1095 1100 I-clinical_variable
≥ 74 75 1101 1102 O
3 76 77 1103 1104 B-lower_bound

Currently 0 9 1105 1114 B-pregnancy
pregnant 10 18 1115 1123 I-pregnancy

Documented 0 10 1124 1134 O
active 11 17 1135 1141 O
systemic 18 26 1142 1150 B-chronic_disease
amyloid 27 34 1151 1158 I-chronic_disease
light 35 40 1159 1164 B-chronic_disease
chain 41 46 1165 1170 I-chronic_disease
amyloidosis 47 58 1171 1182 I-chronic_disease

Documented 0 10 1183 1193 O
evidence 11 19 1194 1202 O
of 20 22 1203 1205 O
PD 23 25 1206 1208 B-chronic_disease
after 26 31 1209 1214 O
achieving 32 41 1215 1224 O
at 42 44 1225 1227 O
least 45 50 1228 1233 O
SD 51 53 1234 1236 B-clinical_variable
for 54 57 1237 1240 O
≥ 58 59 1241 1242 O
1 60 61 1243 1244 B-lower_bound
cycle 62 67 1245 1250 I-lower_bound
during 68 74 1251 1257 O
a 75 76 1258 1259 O
previous 77 85 1260 1268 B-treatment
MM 86 88 1269 1271 I-treatment
regimen 89 96 1272 1279 I-treatment
( 97 98 1280 1281 O
i.e. 98 102 1281 1285 O
, 102 103 1285 1286 O
relapsed 104 112 1287 1295 B-cancer
MM 113 115 1296 1298 I-cancer
) 115 116 1298 1299 O

Documented 0 10 1300 1310 O
evidence 11 19 1311 1319 O
of 20 22 1320 1322 O
relapse 23 30 1323 1330 O
after 31 36 1331 1336 O
≥ 37 38 1337 1338 O
1 39 40 1339 1340 B-lower_bound
previous 41 49 1341 1349 O
line 50 54 1350 1354 O
of 55 57 1355 1357 O
therapy 58 65 1358 1365 B-treatment

Eastern 0 7 1366 1373 B-clinical_variable
Cooperative 8 19 1374 1385 I-clinical_variable
Oncology 20 28 1386 1394 I-clinical_variable
Group 29 34 1395 1400 I-clinical_variable
( 35 36 1401 1402 I-clinical_variable
ECOG 36 40 1402 1406 I-clinical_variable
) 40 41 1406 1407 I-clinical_variable
Performance 42 53 1408 1419 I-clinical_variable
Status 54 60 1420 1426 I-clinical_variable
of 61 63 1427 1429 O
≤ 64 65 1430 1431 O
2 66 67 1432 1433 B-upper_bound

Ejection 0 8 1434 1442 B-clinical_variable
fraction 9 17 1443 1451 I-clinical_variable
( 18 19 1452 1453 I-clinical_variable
EF 19 21 1453 1455 I-clinical_variable
) 21 22 1455 1456 I-clinical_variable
< 23 24 1457 1458 O
50 25 27 1459 1461 B-upper_bound
% 27 28 1461 1462 I-upper_bound
at 29 31 1463 1465 O
Screening 32 41 1466 1475 O

Female 0 6 1476 1482 B-gender
patients 7 15 1483 1491 O
of 16 18 1492 1494 O
child 19 24 1495 1500 O
- 24 25 1500 1501 O
bearing 25 32 1501 1508 O
potential 33 42 1509 1518 O
must 43 47 1519 1523 O
agree 48 53 1524 1529 B-contraception_consent
to 54 56 1530 1532 I-contraception_consent
use 57 60 1533 1536 I-contraception_consent
dual 61 65 1537 1541 I-contraception_consent
methods 66 73 1542 1549 I-contraception_consent
of 74 76 1550 1552 I-contraception_consent
contraception 77 90 1553 1566 I-contraception_consent
and 91 94 1567 1570 O
have 95 99 1571 1575 O
a 100 101 1576 1577 O
negative 102 110 1578 1586 B-pregnancy
serum 111 116 1587 1592 I-pregnancy
pregnancy 117 126 1593 1602 I-pregnancy
test 127 131 1603 1607 O
at 132 134 1608 1610 O
Screening 135 144 1611 1620 O

For 0 3 1621 1624 O
SKd 4 7 1625 1628 O
: 7 8 1628 1629 O
Total 9 14 1630 1635 B-clinical_variable
bilirubin 15 24 1636 1645 I-clinical_variable
< 25 26 1646 1647 O
2x 27 29 1648 1650 B-upper_bound
ULN 30 33 1651 1654 I-upper_bound
( 34 35 1655 1656 O
except 35 41 1656 1662 O
patients 42 50 1663 1671 O
with 51 55 1672 1676 O
Gilbert 56 63 1677 1684 B-chronic_disease
's 63 65 1684 1686 I-chronic_disease
syndrome 66 74 1687 1695 I-chronic_disease
[ 75 76 1696 1697 O
hereditary 76 86 1697 1707 O
indirect 87 95 1708 1716 O
hyperbilirubinemia 96 114 1717 1735 B-chronic_disease
] 114 115 1735 1736 O
who 116 119 1737 1740 O
must 120 124 1741 1745 O
have 125 129 1746 1750 O
a 130 131 1751 1752 O
total 132 137 1753 1758 B-clinical_variable
bilirubin 138 147 1759 1768 I-clinical_variable
of 148 150 1769 1771 O
≤ 151 152 1772 1773 O
3x 153 155 1774 1776 B-upper_bound
ULN 156 159 1777 1780 I-upper_bound
) 159 160 1780 1781 O
and 161 164 1782 1785 O
both 165 169 1786 1790 O
AST 170 173 1791 1794 B-clinical_variable
and 174 177 1795 1798 O
ALT 178 181 1799 1802 B-clinical_variable
< 182 183 1803 1804 O
3.0x 184 188 1805 1809 B-upper_bound
ULN 189 192 1810 1813 I-upper_bound

For 0 3 1814 1817 O
SPd 4 7 1818 1821 O
and 8 11 1822 1825 O
SRd 12 15 1826 1829 O
: 15 16 1829 1830 O
Total 17 22 1831 1836 B-clinical_variable
bilirubin 23 32 1837 1846 I-clinical_variable
< 33 34 1847 1848 O
2x 35 37 1849 1851 B-upper_bound
ULN 38 41 1852 1855 I-upper_bound
( 42 43 1856 1857 O
except 43 49 1857 1863 O
patients 50 58 1864 1872 O
with 59 63 1873 1877 O
Gilbert 64 71 1878 1885 B-chronic_disease
's 71 73 1885 1887 I-chronic_disease
syndrome 74 82 1888 1896 I-chronic_disease
[ 83 84 1897 1898 O
hereditary 84 94 1898 1908 O
indirect 95 103 1909 1917 O
hyperbilirubinemia 104 122 1918 1936 B-chronic_disease
] 122 123 1936 1937 O
who 124 127 1938 1941 O
must 128 132 1942 1946 O
have 133 137 1947 1951 O
a 138 139 1952 1953 O
total 140 145 1954 1959 B-clinical_variable
bilirubin 146 155 1960 1969 I-clinical_variable
of 156 158 1970 1972 O
≤ 159 160 1973 1974 O
3x 161 163 1975 1977 B-upper_bound
ULN 164 167 1978 1981 I-upper_bound
) 167 168 1981 1982 O
and 169 172 1983 1986 O
both 173 177 1987 1991 O
AST 178 181 1992 1995 B-clinical_variable
and 182 185 1996 1999 I-clinical_variable
ALT 186 189 2000 2003 I-clinical_variable
< 190 191 2004 2005 O
2.5x 192 196 2006 2010 B-upper_bound
ULN 197 200 2011 2014 I-upper_bound
) 200 201 2014 2015 O

For 0 3 2016 2019 O
SVd 4 7 2020 2023 O
, 7 8 2023 2024 O
SPVd 9 13 2025 2029 O
and 14 17 2030 2033 O
SDd 18 21 2034 2037 O
): 21 23 2037 2039 O
Total 24 29 2040 2045 B-clinical_variable
bilirubin 30 39 2046 2055 I-clinical_variable
of 40 42 2056 2058 O
≤ 43 44 2059 2060 O
1.5x 45 49 2061 2065 B-upper_bound
ULN 50 53 2066 2069 I-upper_bound
( 54 55 2070 2071 O
except 55 61 2071 2077 O
patients 62 70 2078 2086 O
with 71 75 2087 2091 O
Gilbert 76 83 2092 2099 B-chronic_disease
's 83 85 2099 2101 I-chronic_disease
syndrome 86 94 2102 2110 I-chronic_disease
[ 95 96 2111 2112 O
hereditary 96 106 2112 2122 O
indirect 107 115 2123 2131 O
hyperbilirubinemia 116 134 2132 2150 B-chronic_disease
] 134 135 2150 2151 O
who 136 139 2152 2155 O
must 140 144 2156 2160 O
have 145 149 2161 2165 O
a 150 151 2166 2167 O
total 152 157 2168 2173 B-clinical_variable
bilirubin 158 167 2174 2183 I-clinical_variable
of 168 170 2184 2186 O
≤ 171 172 2187 2188 O
3x 173 175 2189 2191 B-upper_bound
ULN 176 179 2192 2195 I-upper_bound
) 179 180 2195 2196 O
and 181 184 2197 2200 O
both 185 189 2201 2205 O
AST 190 193 2206 2209 B-clinical_variable
and 194 197 2210 2213 O
ALT 198 201 2214 2217 B-clinical_variable
< 202 203 2218 2219 O
2.0x 204 208 2220 2224 B-upper_bound
ULN 209 212 2225 2228 I-upper_bound
) 212 213 2228 2229 O

Histologically 0 14 2230 2244 O
confirmed 15 24 2245 2254 O
diagnosis 25 34 2255 2264 O
, 34 35 2264 2265 O
measurable 36 46 2266 2276 O
disease 47 54 2277 2284 O
and 55 58 2285 2288 O
evidence 59 67 2289 2297 O
of 68 70 2298 2300 O
disease 71 78 2301 2308 O
progression 79 90 2309 2320 O
of 91 93 2321 2323 O
MM 94 96 2324 2326 B-cancer

Hypersensitivity 0 16 2327 2343 O
to 17 19 2344 2346 O
any 20 23 2347 2350 O
of 24 26 2351 2353 O
the 27 30 2354 2357 O
treatments 31 41 2358 2368 B-treatment
for 42 45 2369 2372 O
the 46 49 2373 2376 O
Arm 50 53 2377 2380 O
in 54 56 2381 2383 O
which 57 62 2384 2389 O
the 63 66 2390 2393 O
patient 67 74 2394 2401 O
is 75 77 2402 2404 O
enrolled 78 86 2405 2413 O

In 0 2 2414 2416 O
the 3 6 2417 2420 O
SVd 7 10 2421 2424 O
( 11 12 2425 2426 O
Arm 12 15 2426 2429 O
2 16 17 2430 2431 B-lower_bound
) 17 18 2431 2432 O
only 19 23 2433 2437 O
: 23 24 2437 2438 O
Prior 25 30 2439 2444 O
history 31 38 2445 2452 O
of 39 41 2453 2455 O
neuropathy 42 52 2456 2466 B-chronic_disease
Grade 53 58 2467 2472 I-clinical_variable
> 59 60 2473 2474 O
2 61 62 2475 2476 O
, 62 63 2476 2477 O
or 64 66 2478 2480 O
Grade 67 72 2481 2486 O
2 73 74 2487 2488 O
neuropathy 75 85 2489 2499 O
with 86 90 2500 2504 O
pain 91 95 2505 2509 O
at 96 98 2510 2512 O
screening 99 108 2513 2522 O
( 109 110 2523 2524 O
within 110 116 2524 2530 O
21 117 119 2531 2533 B-upper_bound
days 120 124 2534 2538 I-upper_bound
prior 125 130 2539 2544 I-upper_bound
to 131 133 2545 2547 O
C1D1 134 138 2548 2552 O
) 138 139 2552 2553 O

In 0 2 2554 2556 O
the 3 6 2557 2560 O
expansion 7 16 2561 2570 O
arm 17 20 2571 2574 O
at 21 23 2575 2577 O
RP2D 24 28 2578 2582 O
, 28 29 2582 2583 O
patients 30 38 2584 2592 O
must 39 43 2593 2597 O
not 44 47 2598 2601 O
be 48 50 2602 2604 O
pomalidomide 51 63 2605 2617 B-treatment
refractory 64 74 2618 2628 O

Known 0 5 2629 2634 O
HIV 6 9 2635 2638 B-chronic_disease
infection 10 19 2639 2648 I-chronic_disease
or 20 22 2649 2651 O
HIV 23 26 2652 2655 O
seropositivity 27 41 2656 2670 O

Known 0 5 2671 2676 O
active 6 12 2677 2683 O
hepatitis 13 22 2684 2693 B-chronic_disease
A 23 24 2694 2695 I-chronic_disease
, 24 25 2695 2696 I-chronic_disease
B 26 27 2697 2698 I-chronic_disease
or 28 30 2699 2701 I-chronic_disease
C 31 32 2702 2703 I-chronic_disease

Life 0 4 2704 2708 B-clinical_variable
expectancy 5 15 2709 2719 I-clinical_variable
< 16 17 2720 2721 O
3 18 19 2722 2723 B-upper_bound
months 20 26 2724 2730 I-upper_bound

Male 0 4 2731 2735 B-gender
patients 5 13 2736 2744 I-gender
must 14 18 2745 2749 O
use 19 22 2750 2753 B-contraception_consent
an 23 25 2754 2756 I-contraception_consent
effective 26 35 2757 2766 I-contraception_consent
barrier 36 43 2767 2774 I-contraception_consent
method 44 50 2775 2781 I-contraception_consent
of 51 53 2782 2784 I-contraception_consent
contraception 54 67 2785 2798 I-contraception_consent
if 68 70 2799 2801 O
sexually 71 79 2802 2810 O
active 80 86 2811 2817 O
with 87 91 2818 2822 O
a 92 93 2823 2824 O
female 94 100 2825 2831 B-gender
of 101 103 2832 2834 O
child 104 109 2835 2840 O
- 109 110 2840 2841 O
bearing 110 117 2841 2848 O
potential 118 127 2849 2858 O

Myocardial 0 10 2859 2869 B-chronic_disease
infarction 11 21 2870 2880 I-chronic_disease
( 22 23 2881 2882 I-chronic_disease
MI 23 25 2882 2884 I-chronic_disease
) 25 26 2884 2885 I-chronic_disease
within 27 33 2886 2892 O
3 34 35 2893 2894 B-upper_bound
months 36 42 2895 2901 I-upper_bound
prior 43 48 2902 2907 I-upper_bound
to 49 51 2908 2910 O
C1D1 52 56 2911 2915 O

No 0 2 2916 2918 O
prior 3 8 2919 2924 B-treatment
systemic 9 17 2925 2933 I-treatment
therapy 18 25 2934 2941 I-treatment
for 26 29 2942 2945 O
NDMM 30 34 2946 2950 B-cancer
is 35 37 2951 2953 O
permitted 38 47 2954 2963 O
other 48 53 2964 2969 O
than 54 58 2970 2974 O
pulse 59 64 2975 2980 O
dose 65 69 2981 2985 O
dexamethasone 70 83 2986 2999 B-treatment
( 84 85 3000 3001 O
maximum 85 92 3001 3008 O
dose 93 97 3009 3013 O
of 98 100 3014 3016 O
160 101 104 3017 3020 B-upper_bound
mg 105 107 3021 3023 I-upper_bound
) 107 108 3023 3024 O

Not 0 3 3025 3028 O
refractory 4 14 3029 3039 O
to 15 17 3040 3042 O
bortezomib 18 28 3043 3053 B-treatment
in 29 31 3054 3056 O
their 32 37 3057 3062 O
most 38 42 3063 3067 O
recent 43 49 3068 3074 O
line 50 54 3075 3079 O
of 55 57 3080 3082 O
therapy 58 65 3083 3090 B-treatment

Patients 0 8 3091 3099 O
may 9 12 3100 3103 O
have 13 17 3104 3108 O
received 18 26 3109 3117 O
prior 27 32 3118 3123 B-treatment
bortezomib 33 43 3124 3134 I-treatment
or 44 46 3135 3137 O
carfilzomib 47 58 3138 3149 B-treatment
therapy 59 66 3150 3157 I-treatment
, 66 67 3157 3158 O
however 68 75 3159 3166 O
their 76 81 3167 3172 O
MM 82 84 3173 3175 B-cancer
must 85 89 3176 3180 O
NOT 90 93 3181 3184 O
be 94 96 3185 3187 O
refractory 97 107 3188 3198 O
to 108 110 3199 3201 O
carfilzomib 111 122 3202 3213 O

Patients 0 8 3214 3222 O
must 9 13 3223 3227 O
have 14 18 3228 3232 O
measurable 19 29 3233 3243 B-chronic_disease
disease 30 37 3244 3251 I-chronic_disease

Patients 0 8 3252 3260 O
must 9 13 3261 3265 O
have 14 18 3266 3270 O
symptomatic 19 30 3271 3282 B-cancer
myeloma 31 38 3283 3290 I-cancer
per 39 42 3291 3294 O
IMWG 43 47 3295 3299 O
guidelines 48 58 3300 3310 O
with 59 63 3311 3315 O
either 64 70 3316 3322 O
CRAB 71 75 3323 3327 O
criteria 76 84 3328 3336 O
or 85 87 3337 3339 O
Myeloma 88 95 3340 3347 B-cancer
Defining 96 104 3348 3356 O
Events 105 111 3357 3363 O
and 112 115 3364 3367 O
need 116 120 3368 3372 O
systemic 121 129 3373 3381 B-treatment
therapy 130 137 3382 3389 I-treatment

Patients 0 8 3390 3398 O
must 9 13 3399 3403 O
not 14 17 3404 3407 O
have 18 22 3408 3412 O
received 23 31 3413 3421 O
prior 32 37 3422 3427 B-treatment
daratumumab 38 49 3428 3439 I-treatment
therapy 50 57 3440 3447 I-treatment
( 58 59 3448 3449 O
Cohort 59 65 3449 3455 O
5.3 66 69 3456 3459 O
ONLY 70 74 3460 3464 O
- 75 76 3465 3466 O
dose 77 81 3467 3471 O
expansion 82 91 3472 3481 O
at 92 94 3482 3484 O
RP2D 95 99 3485 3489 O
) 99 100 3489 3490 O

Patients 0 8 3491 3499 O
on 9 11 3500 3502 O
long 12 16 3503 3507 O
- 16 17 3507 3508 O
term 17 21 3508 3512 O
glucocorticoids 22 37 3513 3528 B-treatment
during 38 44 3529 3535 O
Screening 45 54 3536 3545 O
do 55 57 3546 3548 O
not 58 61 3549 3552 O
require 62 69 3553 3560 O
a 70 71 3561 3562 O
washout 72 79 3563 3570 O
period 80 86 3571 3577 O

Patients 0 8 3578 3586 O
receiving 9 18 3587 3596 O
hematopoietic 19 32 3597 3610 B-treatment
growth 33 39 3611 3617 I-treatment
factor 40 46 3618 3624 I-treatment
support 47 54 3625 3632 I-treatment
, 54 55 3632 3633 O
including 56 65 3634 3643 O
erythropoietin 66 80 3644 3658 B-treatment
( 81 82 3659 3660 I-treatment
EPO 82 85 3660 3663 I-treatment
) 85 86 3663 3664 I-treatment
, 86 87 3664 3665 O
darbepoetin 88 99 3666 3677 B-treatment
, 99 100 3677 3678 O
granulocyte 101 112 3679 3690 B-treatment
- 112 113 3690 3691 I-treatment
colony 113 119 3691 3697 I-treatment
stimulating 120 131 3698 3709 I-treatment
factor 132 138 3710 3716 I-treatment
( 139 140 3717 3718 I-treatment
G 140 141 3718 3719 I-treatment
- 141 142 3719 3720 I-treatment
CSF 142 145 3720 3723 I-treatment
) 145 146 3723 3724 I-treatment
, 146 147 3724 3725 O
granulocyte 148 159 3726 3737 B-treatment
macrophagecolony 160 176 3738 3754 I-treatment
stimulating 177 188 3755 3766 I-treatment
factor 189 195 3767 3773 I-treatment
( 196 197 3774 3775 I-treatment
GM 197 199 3775 3777 I-treatment
- 199 200 3777 3778 I-treatment
CSF 200 203 3778 3781 I-treatment
) 203 204 3781 3782 I-treatment
, 204 205 3782 3783 O
and 206 209 3784 3787 O
platelet 210 218 3788 3796 B-treatment
stimulators 219 230 3797 3808 I-treatment
( 231 232 3809 3810 O
e.g. 232 236 3810 3814 O
, 236 237 3814 3815 O
eltrombopag 238 249 3816 3827 B-treatment
or 250 252 3828 3830 O
romiplostim 253 264 3831 3842 B-treatment
) 264 265 3842 3843 O
may 266 269 3844 3847 O
continue 270 278 3848 3856 O
to 279 281 3857 3859 O
do 282 284 3860 3862 O
so 285 287 3863 3865 O

Patients 0 8 3866 3874 O
who 9 12 3875 3878 O
received 13 21 3879 3887 O
≥ 22 23 3888 3889 O
1 24 25 3890 3891 B-lower_bound
prior 26 31 3892 3897 B-treatment
therapeutic 32 43 3898 3909 I-treatment
regimen 44 51 3910 3917 I-treatment
( 52 53 3918 3919 O
prior 53 58 3919 3924 B-treatment
lenalidomide 59 71 3925 3937 I-treatment
is 72 74 3938 3940 O
allowed 75 82 3941 3948 O
as 83 85 3949 3951 O
long 86 90 3952 3956 O
as 91 93 3957 3959 O
patient 94 101 3960 3967 O
's 101 103 3967 3969 O
MM 104 106 3970 3972 B-cancer
was 107 110 3973 3976 O
not 111 114 3977 3980 O
refractory 115 125 3981 3991 O
to 126 128 3992 3994 O
prior 129 134 3995 4000 O
lenalidomide 135 147 4001 4013 O

Patients 0 8 4014 4022 O
who 9 12 4023 4026 O
received 13 21 4027 4035 O
≥ 22 23 4036 4037 O
3 24 25 4038 4039 B-lower_bound
prior 26 31 4040 4045 B-treatment
lines 32 37 4046 4051 I-treatment
of 38 40 4052 4054 I-treatment
therapy 41 48 4055 4062 I-treatment
, 48 49 4062 4063 O
including 50 59 4064 4073 O
a 60 61 4074 4075 O
PI 62 64 4076 4078 O
and 65 68 4079 4082 O
an 69 71 4083 4085 O
IMiD 72 76 4086 4090 O
, 76 77 4090 4091 O
or 78 80 4092 4094 O
patients 81 89 4095 4103 O
with 90 94 4104 4108 O
MM 95 97 4109 4111 B-cancer
refractory 98 108 4112 4122 O
to 109 111 4123 4125 O
both 112 116 4126 4130 O
a 117 118 4131 4132 O
PI 119 121 4133 4135 O
and 122 125 4136 4139 O
an 126 128 4140 4142 O
IMiD 129 133 4143 4147 O

Patients 0 8 4148 4156 O
whose 9 14 4157 4162 O
MM 15 17 4163 4165 B-cancer
is 18 20 4166 4168 O
relapsing 21 30 4169 4178 O
after 31 36 4179 4184 O
≥ 37 38 4185 4186 O
1 39 40 4187 4188 B-lower_bound
prior 41 46 4189 4194 B-treatment
therapy 47 54 4195 4202 I-treatment
with 55 59 4203 4207 O
progression 60 71 4208 4219 O
on 72 74 4220 4222 O
their 75 80 4223 4228 O
last 81 85 4229 4233 B-treatment
therapy 86 93 4234 4241 I-treatment

Patients 0 8 4242 4250 O
with 9 13 4251 4255 O
history 14 21 4256 4263 O
of 22 24 4264 4266 O
SCC 25 28 4267 4270 B-cancer
with 29 33 4271 4275 O
residual 34 42 4276 4284 B-chronic_disease
paraplegia 43 53 4285 4295 I-chronic_disease
( 54 55 4296 4297 O
Dose 55 59 4297 4301 O
Escalation 60 70 4302 4312 O
Phase 71 76 4313 4318 O
only 77 81 4319 4323 O
) 81 82 4323 4324 O

Previously 0 10 4325 4335 O
undergone 11 20 4336 4345 O
≥ 21 22 4346 4347 O
2 23 24 4348 4349 B-lower_bound
cycles 25 31 4350 4356 I-lower_bound
of 32 34 4357 4359 O
lenalidomide 35 47 4360 4372 B-treatment
and 48 51 4373 4376 O
a 52 53 4377 4378 O
proteasome 54 64 4379 4389 B-treatment
inhibitor 65 74 4390 4399 I-treatment
( 75 76 4400 4401 O
in 76 78 4401 4403 O
separate 79 87 4404 4412 O
therapeutic 88 99 4413 4424 O
regimens 100 108 4425 4433 O
[ 109 110 4434 4435 O
not 110 113 4435 4438 O
for 114 117 4439 4442 O
maintenance 118 129 4443 4454 O
] 129 130 4454 4455 O
or 131 133 4456 4458 O
in 134 136 4459 4461 O
combination 137 148 4462 4473 O
) 148 149 4473 4474 O

Prior 0 5 4475 4480 B-treatment
autologous 6 16 4481 4491 I-treatment
stem 17 21 4492 4496 I-treatment
cell 22 26 4497 4501 I-treatment
transplantation 27 42 4502 4517 I-treatment
< 43 44 4518 4519 O
1 45 46 4520 4521 B-upper_bound
month 47 52 4522 4527 I-upper_bound
, 52 53 4527 4528 O
or 54 56 4529 4531 O
allogeneic 57 67 4532 4542 B-treatment
stem 68 72 4543 4547 I-treatment
cell 73 77 4548 4552 I-treatment
transplantation 78 93 4553 4568 I-treatment
< 94 95 4569 4570 O
3 96 97 4571 4572 B-upper_bound
months 98 104 4573 4579 I-upper_bound
prior 105 110 4580 4585 I-upper_bound
to 111 113 4586 4588 O
C1D1 114 118 4589 4593 O

Prior 0 5 4594 4599 O
exposure 6 14 4600 4608 O
to 15 17 4609 4611 O
a 18 19 4612 4613 O
SINE 20 24 4614 4618 O
compound 25 33 4619 4627 O
, 33 34 4627 4628 O
including 35 44 4629 4638 O
selinexor 45 54 4639 4648 B-treatment

Radiation 0 9 4649 4658 B-treatment
, 9 10 4658 4659 O
chemotherapy 11 23 4660 4672 B-treatment
, 23 24 4672 4673 O
or 25 27 4674 4676 O
immunotherapy 28 41 4677 4690 B-treatment
or 42 44 4691 4693 O
any 45 48 4694 4697 O
other 49 54 4698 4703 O
anticancer 55 65 4704 4714 B-treatment
therapy 66 73 4715 4722 I-treatment
≤ 74 75 4723 4724 O
2 76 77 4725 4726 B-upper_bound
weeks 78 83 4727 4732 I-upper_bound
prior 84 89 4733 4738 I-upper_bound
to 90 92 4739 4741 O
C1D1 93 97 4742 4746 B-treatment
, 97 98 4746 4747 O
and 99 102 4748 4751 O
radio 103 108 4752 4757 B-treatment
- 108 109 4757 4758 I-treatment
immunotherapy 109 122 4758 4771 I-treatment
within 123 129 4772 4778 O
6 130 131 4779 4780 B-upper_bound
weeks 132 137 4781 4786 I-upper_bound
prior 138 143 4787 4792 I-upper_bound
to 144 146 4793 4795 O
C1D1 147 151 4796 4800 O

Relapsed 0 8 4801 4809 B-cancer
or 9 11 4810 4812 I-cancer
refractory 12 22 4813 4823 I-cancer
MM 23 25 4824 4826 I-cancer

Serum 0 5 4827 4832 B-clinical_variable
FLC 6 9 4833 4836 I-clinical_variable
≥ 10 11 4837 4838 O
100 12 15 4839 4842 B-lower_bound
mg 16 18 4843 4845 I-lower_bound
/ 18 19 4845 4846 I-lower_bound
L 19 20 4846 4847 I-lower_bound
, 20 21 4847 4848 O
provided 22 30 4849 4857 O
that 31 35 4858 4862 O
FLC 36 39 4863 4866 B-clinical_variable
ratio 40 45 4867 4872 I-clinical_variable
is 46 48 4873 4875 O
abnormal 49 57 4876 4884 O

Serum 0 5 4885 4890 B-clinical_variable
M 6 7 4891 4892 I-clinical_variable
- 7 8 4892 4893 I-clinical_variable
protein 8 15 4893 4900 I-clinical_variable
≥ 16 17 4901 4902 O
0.5 18 21 4903 4906 B-lower_bound
g 22 23 4907 4908 I-lower_bound
/ 23 24 4908 4909 I-lower_bound
dL 24 26 4909 4911 I-lower_bound
by 27 29 4912 4914 O
serum 30 35 4915 4920 B-treatment
protein 36 43 4921 4928 I-treatment
electrophoresis 44 59 4929 4944 I-treatment
( 60 61 4945 4946 I-treatment
SPEP 61 65 4946 4950 I-treatment
) 65 66 4950 4951 I-treatment
or 67 69 4952 4954 O
, 69 70 4954 4955 O
for 71 74 4956 4959 O
IgA 75 78 4960 4963 B-cancer
myeloma 79 86 4964 4971 I-cancer
, 86 87 4971 4972 O
by 88 90 4973 4975 O
quantitative 91 103 4976 4988 O
IgA 104 107 4989 4992 O

Smoldering 0 10 4993 5003 B-cancer
MM 11 13 5004 5006 I-cancer

Symptomatic 0 11 5007 5018 O
MM 12 14 5019 5021 B-cancer
, 14 15 5021 5022 O
based 16 21 5023 5028 O
on 22 24 5029 5031 O
IMWG 25 29 5032 5036 O
guidelines 30 40 5037 5047 O

Symptomatic 0 11 5048 5059 B-chronic_disease
ischemia 12 20 5060 5068 I-chronic_disease

Treatment 0 9 5069 5078 B-treatment
with 10 14 5079 5083 I-treatment
an 15 17 5084 5086 I-treatment
investigational 18 33 5087 5102 I-treatment
anti 34 38 5103 5107 I-treatment
- 38 39 5107 5108 I-treatment
cancer 39 45 5108 5114 I-treatment
therapy 46 53 5115 5122 I-treatment
within 54 60 5123 5129 O
3 61 62 5130 5131 B-upper_bound
weeks 63 68 5132 5137 I-upper_bound
prior 69 74 5138 5143 I-upper_bound
to 75 77 5144 5146 O
C1D1 78 82 5147 5151 O

Uncontrolled 0 12 5152 5164 B-chronic_disease
active 13 19 5165 5171 I-chronic_disease
hypertension 20 32 5172 5184 I-chronic_disease

Uncontrolled 0 12 5185 5197 O
active 13 19 5198 5204 B-chronic_disease
infection 20 29 5205 5214 I-chronic_disease
requiring 30 39 5215 5224 O
parenteral 40 50 5225 5235 B-treatment
antibiotics 51 62 5236 5247 I-treatment
, 62 63 5247 5248 O
antivirals 64 74 5249 5259 B-treatment
, 74 75 5259 5260 O
or 76 78 5261 5263 O
antifungals 79 90 5264 5275 B-treatment
within 91 97 5276 5282 O
one 98 101 5283 5286 B-upper_bound
week 102 106 5287 5291 I-upper_bound
prior 107 112 5292 5297 I-upper_bound
to 113 115 5298 5300 O
first 116 121 5301 5306 O
dose 122 126 5307 5311 O

Uncontrolled 0 12 5312 5324 O
clinically 13 23 5325 5335 O
- 23 24 5335 5336 O
significant 24 35 5336 5347 O
conduction 36 46 5348 5358 B-chronic_disease
abnormalities 47 60 5359 5372 I-chronic_disease
( 61 62 5373 5374 O
e.g. 62 66 5374 5378 O
, 66 67 5378 5379 O
patients 68 76 5380 5388 O
with 77 81 5389 5393 O
ventricular 82 93 5394 5405 B-chronic_disease
tachycardia 94 105 5406 5417 I-chronic_disease
on 106 108 5418 5420 O
antiarrhythmics 109 124 5421 5436 B-treatment

Urinary 0 7 5437 5444 B-clinical_variable
M 8 9 5445 5446 I-clinical_variable
- 9 10 5446 5447 I-clinical_variable
protein 10 17 5447 5454 I-clinical_variable
excretion 18 27 5455 5464 O
at 28 30 5465 5467 O
least 31 36 5468 5473 O
200 37 40 5474 5477 B-lower_bound
mg/24 41 46 5478 5483 I-lower_bound
hours 47 52 5484 5489 I-lower_bound

for 0 3 5490 5493 O
patients 4 12 5494 5502 O
in 13 15 5503 5505 O
whom 16 20 5506 5510 O
≥ 21 22 5511 5512 O
50 23 25 5513 5515 B-lower_bound
% 25 26 5515 5516 I-lower_bound
of 27 29 5517 5519 O
bone 30 34 5520 5524 B-clinical_variable
marrow 35 41 5525 5531 I-clinical_variable
nucleated 42 51 5532 5541 I-clinical_variable
cells 52 57 5542 5547 I-clinical_variable
are 58 61 5548 5551 O
plasma 62 68 5552 5558 O
cells 69 74 5559 5564 O

hemoglobin 0 10 5565 5575 B-clinical_variable
( 11 12 5576 5577 I-clinical_variable
Hb 12 14 5577 5579 I-clinical_variable
) 14 15 5579 5580 I-clinical_variable
≥ 16 17 5581 5582 O
8.0 18 21 5583 5586 B-lower_bound
g 22 23 5587 5588 I-lower_bound
/ 23 24 5588 5589 I-lower_bound
dL 24 26 5589 5591 I-lower_bound

patients 0 8 5592 5600 O
in 9 11 5601 5603 O
the 12 15 5604 5607 O
escalation 16 26 5608 5618 O
cohorts 27 34 5619 5626 O
must 35 39 5627 5631 O
be 40 42 5632 5634 O
platelet 43 51 5635 5643 B-clinical_variable
transfusion 52 63 5644 5655 I-clinical_variable
independent 64 75 5656 5667 I-clinical_variable
for 76 79 5668 5671 O
> 80 81 5672 5673 O
1 82 83 5674 5675 B-lower_bound
week 84 88 5676 5680 I-lower_bound
in 89 91 5681 5683 O
order 92 97 5684 5689 O
to 98 100 5690 5692 O
be 101 103 5693 5695 O
enrolled 104 112 5696 5704 O
in 113 115 5705 5707 O
the 116 119 5708 5711 O
study 120 125 5712 5717 O

platelet 0 8 5718 5726 B-clinical_variable
count 9 14 5727 5732 I-clinical_variable
≥ 15 16 5733 5734 O
75,000 17 23 5735 5741 B-lower_bound
/ 23 24 5741 5742 I-lower_bound
mm3 24 27 5742 5745 I-lower_bound

platelet 0 8 5746 5754 B-clinical_variable
counts 9 15 5755 5761 I-clinical_variable
> 16 17 5762 5763 O
50,000 18 24 5764 5770 B-lower_bound
/ 24 25 5770 5771 I-lower_bound
mm3 25 28 5771 5774 I-lower_bound

platelets 0 9 5775 5784 B-clinical_variable
or 10 12 5785 5787 O
≥ 13 14 5788 5789 O
30,000 15 21 5790 5796 B-lower_bound
/ 21 22 5796 5797 I-lower_bound
mm3 22 25 5797 5800 I-lower_bound
are 26 29 5801 5804 O
acceptable 30 40 5805 5815 O
for 41 44 5816 5819 O
expansion 45 54 5820 5829 O
cohorts 55 62 5830 5837 O

total 0 5 5838 5843 B-clinical_variable
white 6 11 5844 5849 I-clinical_variable
blood 12 17 5850 5855 I-clinical_variable
cell 18 22 5856 5860 I-clinical_variable
( 23 24 5861 5862 I-clinical_variable
WBC 24 27 5862 5865 I-clinical_variable
) 27 28 5865 5866 I-clinical_variable
count 29 34 5867 5872 I-clinical_variable
≥ 35 36 5873 5874 O
1,500 37 42 5875 5880 B-lower_bound
/ 42 43 5880 5881 I-lower_bound
mm3 43 46 5881 5884 I-lower_bound

≤ 0 1 5885 5886 O
25 2 4 5887 5889 B-upper_bound
% 4 5 5889 5890 I-upper_bound
response 6 14 5891 5899 O
( 15 16 5900 5901 O
i.e. 16 20 5901 5905 O
, 20 21 5905 5906 O
patients 22 30 5907 5915 O
never 31 36 5916 5921 O
achieved 37 45 5922 5930 O
≥ 46 47 5931 5932 O
MR 48 50 5933 5935 O
) 50 51 5935 5936 O
or 52 54 5937 5939 O
PD 55 57 5940 5942 O
during 58 64 5943 5949 O
or 65 67 5950 5952 O
within 68 74 5953 5959 O
60 75 77 5960 5962 B-upper_bound
days 78 82 5963 5967 I-upper_bound
from 83 87 5968 5972 O
the 88 91 5973 5976 O
end 92 95 5977 5980 O
of 96 98 5981 5983 O
the 99 102 5984 5987 O
most 103 107 5988 5992 O
recent 108 114 5993 5999 O
MM 115 117 6000 6002 B-cancer
regimen 118 125 6003 6010 O
( 126 127 6011 6012 O
i.e. 127 131 6012 6016 O
, 131 132 6016 6017 O
refractory 133 143 6018 6028 B-cancer
MM 144 146 6029 6031 I-cancer
) 146 147 6031 6032 O

≥ 0 1 6033 6034 O
20 2 4 6035 6037 B-lower_bound
mL 5 7 6038 6040 I-lower_bound
/ 7 8 6040 6041 I-lower_bound
min 8 11 6041 6044 I-lower_bound
for 12 15 6045 6048 O
SVd 16 19 6049 6052 O
, 19 20 6052 6053 O
SPVd 21 25 6054 6058 O
, 25 26 6058 6059 O
and 27 30 6060 6063 O
SDd 31 34 6064 6067 O
Arms 35 39 6068 6072 O

≥ 0 1 6073 6074 O
45 2 4 6075 6077 B-lower_bound
mL 5 7 6078 6080 I-lower_bound
/ 7 8 6080 6081 I-lower_bound
min 8 11 6081 6084 I-lower_bound
for 12 15 6085 6088 O
SPd 16 19 6089 6092 O
Arm 20 23 6093 6096 O
( 24 25 6097 6098 O
as 25 27 6098 6100 O
requested 28 37 6101 6110 O
by 38 40 6111 6113 O
the 41 44 6114 6117 O
manufacturer 45 57 6118 6130 O
) 57 58 6130 6131 O

